LYNAVOY (Linerixibat) Patent Expiration, LOE Window & CMS Spending

LYNAVOY (Linerixibat) by Intercept: FDA Orange Book core substance LOE 2031-09-06 (last listed 2033-03-17), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $12,083 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorIntercept
FDA Application & PathwayN220295 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-09-06
Last Listed Patent or Exclusivity Date2033-03-17
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($12,083 intro WAC)